HNN3.0

Project cooperationUpdated on 22 January 2026

Saliva-based metabolomics platform & expertise for Horizon research and innovation projects

cofounder/CSO at Maven Health

Zurich, Switzerland

About

We are an EPFL spin-off developing a scalable, non-invasive metabolomics platform based on saliva analysis using nuclear magnetic resonance (NMR) spectroscopy combined with automated data processing and interpretation algorithms.

Our technology enables robust quantification of a broad panel of metabolites from saliva with minimal sample preparation, making it well suited for preventive health, longitudinal monitoring, and population-level studies. Beyond the analytical layer, we provide a secure digital platform that transforms complex metabolomic data into interpretable, action-oriented insights for professional use.

We are interested in project cooperation within Horizon Europe and related programmes, and can contribute as a technology provider, scientific partner, or application partner. We are particularly interested in collaborations involving:

  • Preventive and personalised healthcare

  • Metabolic health, nutrition, and lifestyle interventions

  • Non-invasive diagnostics and monitoring

  • Digital health platforms and data-driven health insights

  • Validation of novel biomarkers and real-world pilot studies

What we offer to a consortium:

  • Proprietary saliva-based metabolomics technology (NMR-based)

  • Expertise in saliva analytics, metabolomics, and biomarker interpretation

  • Automated data processing and scalable platform infrastructure

  • Experience with human studies and real-world validation

  • An asset-light laboratory model leveraging established NMR partners

We are open to joining existing consortia or co-developing new project proposals where non-invasive metabolic profiling and actionable health insights can add scientific, clinical, or societal value.

Topic

  • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
  • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

Organisation

Maven Health

Start-up

Zurich, Switzerland

Similar opportunities

  • Project cooperation

    Advancing Horizon Europe projects through microbiota and metabolomics for translational and clinical research

    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Silvia Angeletti

    Full Professor Clinical Pathology and Head of Laboratory Unit at Fondazione Policlinico Universitario Campus Bio-Medico

    Rome, Italy

  • Project cooperation

    Mass Spetrometry Metabolomics: Bioactive Metabolites and Host-Microbiota Interactions

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Zdenek Kamenik

    Research group leader at Institute of Microbiology Czech Acad Sci

    Praha, Czech Republic

  • Project cooperation

    Health projects at Eurecat

    • Consortium/Coordinator seeks Partners
    • Partner seeks Consortium/Coordinator
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults

    MARTA SANS VALLS

    European Programme Manager at Fundacio Eurecat

    Barcelona, Spain